ALC: Alcon Inc insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Clinical trial readouts
3 Phase 2 or 3 trials by Alcon Inc with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2027-01 (est.) | Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preserva | Ocular Hyperemia | Phase 3 | 178 | Recruiting | NCT07578363 |
| 2027-02 (est.) | Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preserva | Ocular Hyperemia | Phase 3 | 230 | Recruiting | NCT07531043 |
| 2027-04 (est.) | AR-14034 SR implant lower dose | Neovascular Age-related Macular Degeneration (nAMD) | Phase 1/2 | 139 | Enrollment complete | NCT05769153 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.